Haematology (Scholarly Publications)
Browse by
Recent Submissions
-
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma
(2022)Aims: We have recently described a novel guanidinium-based compound, VP79s, which induces cytotoxicity in various cancer cell lines. Here, we aim to investigate the activity of VP79s and associated mechanisms of action in ... -
Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning
(2021)Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) is the commonest B-cell malignancy affecting Caucasians, with a variable national incidence depending on the ethnic composition and age profile of ... -
The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party
(2019)More than 60% of patients with non-Hodgkin lymphoma (NHL) are age>60 years at presentation. The purpose of thisstudy was to compare the potential risks and benefits of allogeneic hematopoietic cell transplantation (alloHCT) ... -
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
(2018)The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective ... -
Melphalan 140 mg/m2or 200 mg/m2for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party
(2018)Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived ...